Overview
Pharmacokinetics of CRD007 in Patients With Abdominal Aorta Aneurisms.
Status:
Completed
Completed
Trial end date:
2012-11-01
2012-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of the study is to determine the plasma levels of CRD007 in patients with abdominal aortic aneurysms after the administration of single doses of tablets containing 10, 25 and 40 mg CRD007.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
RSPR Pharma AB
Criteria
Inclusion Criteria:- Infra-renal abdominal aortic aneurysm
Exclusion Criteria:
- Significant concurrent disease or medical conditions that are deemed to interfere with
the pharmacokinetics or the safety of CRD007 conduct of the trial